Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Tango Therapeutics Inc. — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.29 (market cap $159.50M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 23.5× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| RDTE | TNGX | |
|---|---|---|
Market Cap | $159.50M | $3.75B |
Volume | 55,754 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $32.90 |
52-Week Low | $25.43 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE (Roundhill Russell 2000 0DTE Covered Call Strategy ETF) trades at $25.91, down 0.54% with bearish technical indicators showing 17 sell signals versus 0 buy signals. The ETF faces capital erosion concerns despite offering high dividend yields through its covered call strategy on Russell 2000 small-cap stocks. Recent dividend payments have ranged from $0.10 to $0.23 per share, but the fund's income generation comes with significant price depreciation risk.
The outlook remains challenging as technical analysis indicates strong bearish momentum with moving averages unanimously signaling sell. Fundamental data is limited but the covered call strategy exposes investors to capped upside potential during market rallies while providing limited downside protection. Key risks include small-cap volatility and the structural limitations of 0DTE options strategies in generating sustainable income.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
